Add on Effect of Fesoterodine and Vibegron for Male Overactive Bladder Treated with Tadalafil Multicenter Randomized Comparative Study

Add on Effect of Fesoterodine and Vibegron for Male Overactive Bladder Treated with Tadalafil Multicenter Randomized Comparative Study - FAVORITE Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038483

Enrollment

280

Registered

2019-12-31

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Bivegron 50mg 12weeks Fesoterodin 4mg 12weeks No add-on treatment

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male OAB patients with over 8 weeks of tadalafil treatment

Exclusion criteria

Exclusion criteria: Over 100ml of postvoid residual

Design outcomes

Primary

Measure	Time frame
Overactive bladder symptom score	—

Secondary

Measure	Time frame
IPSS and frequency volume chart	—

Countries

Japan

Contacts

Public ContactNaoki Wada

Asahikawa Medical University Renal and Urologic Surgery

nwada@asahikawa-med.ac.jp0166-68-2533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026